Expert recommendations for pancreatitis/pancreatic necrosis treatment after L-asparaginase in children with acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Expert recommendations for pancreatitis/pancreatic necrosis treatment after L-asparaginase in children with acute lymphoblastic leukemia

Published:2024-04-01 Issue:2 Volume:19 Page:141-146
ISSN:2413-4023
Container-title:Oncohematology
language:
Short-container-title:Onkogematologiâ

Author:

Valiev T. T.¹^ORCID,Kumirova E. V.²^ORCID,Rozinov V. M.³^ORCID,Panferova T. R.⁴^ORCID,Khvorostov I. N.⁵^ORCID,Kondratchik K. L.⁵^ORCID,Fuks O. Yu.⁵^ORCID,Kerimov P. A.⁴^ORCID,Matinyan N. V.⁶^ORCID,Belyaeva A. V.³^ORCID,Efremenkov A. M.⁷^ORCID,Bystrova A. A.⁵^ORCID,Kurkin A. P.⁵^ORCID,Gorev V. V.⁵^ORCID

Affiliation:

1. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

2. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Morozov Children’s City Clinical Hospital, Moscow Healthcare Department; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

3. Yu.E. Veltishchev Research and Clinical Institute for Pediatrics and Pediatric Surgery, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

4. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

5. Morozov Children’s City Clinical Hospital, Moscow Healthcare Department

6. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

7. Central Clinical Hospital with Polyclinic, Presidential Administration of the Russian Federation

Abstract

L-asparaginase is one of the most effective drugs in pediatric and adult acute lymphoblastic leukemia treatment. But drug side effects are an important problem. pancreatitis and pancreatic necrosis are not common (2–18 %) complication, but high chance of severe disease with fatal outcome make to bring in careful attention of pediatric oncologists-hematologists, surgeons, intensivists, radiologists. Recognizing multidisciplinary importance of this problem, at June 21st, 2023 at Morozov Children’s Clinical hospital a Round table on pancreatitis/pancreatic necrosis after L-asparaginase use was organized. This article presents expert recommendations from federal and regional clinics in diagnosis and treatment of such severe complication.

Publisher

Publishing House ABV Press

Reference16 articles.

1. Campbell M., Kiss C., Zimmermann M. et al. Childhood acute lymphoblastic leukemia: results of the randomized acute lymphoblastic leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 trial. J Clin Oncol 2023;41(19):3499–511. DOI: 10.1200/JCO.22.01760

2. Valiev T.T., Shervashidze M.A., Osipova I.V. et al. ALL-IC BFM 2002 protocol: treatment results of acute lymphoblastic leukemia in children in a multicenter clinical trial. Klinicheskaya onkogematologiya. Fundamentalnye issledovaniya i klinicheskaya praktika = Clinical Oncohematology. Basic Research and Clinical Practice 2022;15(2):119–29. (In Russ.).

3. Wetzler M., Sanford B., Kurtzberg J. et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood 2007;109(10):4164–7. DOI: 10.1182/blood-2006-09-045351

4. Korkina Yu.S., Valiev Т.Т. Asparaginase drugs: a new view of the mechanism of action, side effects and experience in BFM (Berlin–Frankfurt–Mȕnster) protocols. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2021;8(4):81–9. (In Russ.). DOI: 10.21682/2311-1267-2021-8-4-81-89

5. Egler R.A., Ahuja S.P., Matloub Y. et al. L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmacol Pharmacother 2016;7(2):62–71. DOI: 10.4103/0976-500X.184769